Ondansetron as a Strategy for Reducing Propofol Injection Pain in Pediatrics: a Randomized Controlled Trial

Model scores of the 29,894 trials active now.

Model score 24% for any early termination, 12% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 16% of the time (1,198 trials).

Finished trial that started in 2015 or later: the model never saw it during training.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2023-08-03. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: painchronicsubjectssyndromeopioid
  Phrases that lowered it: patientstrialsignstatusprovided
• Sponsor's past termination rate: 17.7% (raises risk) · Sponsor's track record
• Accepts healthy volunteers: No (raises risk) · Who can join
• Phase: 2 (raises risk) · Design
• Blinding: single (lowers risk) · Design
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Sponsor's past trials: 677 (raises risk) · Sponsor's track record
• Primary purpose: prevention (lowers risk) · Design
• Disease area, cancer: No (lowers risk) · Disease area
• Trials the sponsor started in the prior 2 years: 124 (lowers risk) · Sponsor's track record
• Design: parallel (raises risk) · Design
• Drug's FAERS reports marked serious: 69.9% (lowers risk) · Drug's FDA history
• Drug's FAERS reports in the prior 12 months: 21863 (raises risk) · Drug's FDA history
• Drug's FAERS reports with a death: 11.1% (lowers risk) · Drug's FDA history
• Maximum age: 17 (raises risk) · Who can join
• Drug's FAERS reports before start: 228535 (lowers risk) · Drug's FDA history
• Minimum age: 2 (lowers risk) · Who can join
• Number of arms: 2 (raises risk) · Design
• Has a data monitoring committee: No (lowers risk) · Design
• Collaborators: 0 (raises risk) · Design
• Responsible party: principal investigator (lowers risk) · Design
• Drugs with FDA adverse-event history: 2 (lowers risk) · Drug's FDA history

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Ketofol Versus Fentofol for Procedural Sedation in the Pediatric Emergency Department NCT02079090 · started 2014 · scored riskier than 77% of active trials completed
• A Comparison of Midazolam and Zolpidem as Oral Premedication in Children NCT02096900 · started 2014 · scored riskier than 46% of active trials completed
• A Multi-Center Study of the Efficacy, Pharmacokinetics (PK) and Pharmacodynamics (PD) of IV Acetaminophen for the Treatment of Acute Pain in Pediatric Patients NCT01635101 · started 2012 · scored riskier than 42% of active trials completed
• Opioid Sparing Analgesia: Dexmedetomidine Versus Lidocaine for Intracranial Surgeries in Children NCT04535089 · started 2020 · scored riskier than 7% of active trials completed
• Comparison Between Ondansetron 8 mg and Lidocain 40 mg in Preventing Pain Due to Propofol Injection NCT03134612 · started 2016 · scored riskier than 7% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.